ID PHARMA CO LTD has a total of 32 patent applications. It increased the IP activity by 150.0%. Its first patent ever was published in 2006. It filed its patents most often in EPO (European Patent Office), United States and Japan. Its main competitors in its focus markets biotechnology and pharmaceuticals are EDITAS MEDICINE INC, AGTC GENE TECHNOLOGY COMPANY L and SHENZHEN ISTEM REGENERATIVE MEDICINE SCI TECH CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | United States | 6 | |
#3 | Japan | 5 | |
#4 | WIPO (World Intellectual Property Organization) | 5 | |
#5 | Australia | 3 | |
#6 | China | 3 | |
#7 | Canada | 1 | |
#8 | Hungary | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Hasegawa Mamoru | 15 |
#2 | Inoue Makoto | 13 |
#3 | Saeki Koichi | 9 |
#4 | Ban Hiroshi | 9 |
#5 | Griesenbach Uta | 7 |
#6 | Yonemitsu Yoshikazu | 7 |
#7 | Kusano Kohji | 7 |
#8 | Mori Toyotaka | 6 |
#9 | Fusaki Noemi | 6 |
#10 | Alton Eric W | 5 |
Publication | Filing date | Title |
---|---|---|
WO2020022476A1 | System for highly efficient modification of target sequences | |
WO2019017438A1 | Polynucleotide for modifying target sequence and use thereof | |
JP2019014696A | Therapeutic composition of cancer | |
WO2017082174A1 | Improved paramyxovirus vector | |
US2018195085A1 | Improved negative-strand rna viral vector | |
AU2014324233A1 | Method for improving efficiency of inducing pluripotent stem cell | |
EP2322611A1 | Method for production of reprogrammed cell using chromosomally unintegrated virus vector |